Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Treg cells in different forms of uterine cancer.

Hou F, Ma D, Cui B.

Clin Chim Acta. 2013 Jan 16;415:337-40. doi: 10.1016/j.cca.2012.11.004. Epub 2012 Nov 23. Review.

PMID:
23178746
2.

Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.

Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S.

Cancer Sci. 2007 Jun;98(6):874-81. Epub 2007 Apr 13.

3.

Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer.

Loddenkemper C, Hoffmann C, Stanke J, Nagorsen D, Baron U, Olek S, Huehn J, Ritz JP, Stein H, Kaufmann AM, Schneider A, Cichon G.

Cancer Sci. 2009 Jun;100(6):1112-7.

PMID:
19514119
4.

Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer.

Battaglia A, Buzzonetti A, Monego G, Peri L, Ferrandina G, Fanfani F, Scambia G, Fattorossi A.

Immunology. 2008 Jan;123(1):129-38. Epub 2007 Nov 20.

5.

Development and maintenance of regulatory T cells.

Ohkura N, Kitagawa Y, Sakaguchi S.

Immunity. 2013 Mar 21;38(3):414-23. doi: 10.1016/j.immuni.2013.03.002. Review.

6.

Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H.

Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Review.

PMID:
18058571
7.

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A.

Cancer Res. 2007 Jun 15;67(12):5929-39.

8.

CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase.

Li W, Li B, Fan W, Geng L, Li X, Li L, Huang Z, Li S.

J Reprod Immunol. 2009 Jun;80(1-2):1-11. doi: 10.1016/j.jri.2008.11.006. Epub 2009 Apr 11.

PMID:
19362742
9.

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.

Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A.

Cancer Immunol Immunother. 2009 Sep;58(9):1363-73. doi: 10.1007/s00262-008-0646-7. Epub 2009 Jan 27.

PMID:
19172271
10.

FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.

Kobayashi N, Kubota K, Kato S, Watanabe S, Shimamura T, Kirikoshi H, Saito S, Ueda M, Endo I, Inayama Y, Maeda S, Nakajima A.

Pancreatology. 2010;10(5):631-40. doi: 10.1159/000308966. Epub 2010 Nov 5.

PMID:
21051918
11.

Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes.

Kornete M, Piccirillo CA.

Autoimmun Rev. 2011 Dec;11(2):104-11. doi: 10.1016/j.autrev.2011.08.007. Epub 2011 Aug 22. Review.

PMID:
21875694
12.

Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.

Singh AK, Seavey CN, Horvath KA, Mohiuddin MM.

Xenotransplantation. 2012 Mar-Apr;19(2):102-11. doi: 10.1111/j.1399-3089.2012.00697.x.

PMID:
22497512
13.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

14.

Targeting regulatory T cells in tumors.

Liu C, Workman CJ, Vignali DA.

FEBS J. 2016 Jul;283(14):2731-48. doi: 10.1111/febs.13656. Epub 2016 Mar 1. Review.

15.

Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice.

Suffner J, Hochweller K, Kühnle MC, Li X, Kroczek RA, Garbi N, Hämmerling GJ.

J Immunol. 2010 Feb 15;184(4):1810-20. doi: 10.4049/jimmunol.0902420. Epub 2010 Jan 18.

16.

Thymic and peripheral differentiation of regulatory T cells.

Lee HM, Bautista JL, Hsieh CS.

Adv Immunol. 2011;112:25-71. doi: 10.1016/B978-0-12-387827-4.00002-4. Review.

PMID:
22118406
17.

CD25+ CD4+ regulatory T-cells in cancer.

Linehan DC, Goedegebuure PS.

Immunol Res. 2005;32(1-3):155-68. Review.

PMID:
16106066
18.

Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.

Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E, Fietta AM.

Hum Immunol. 2006 Jan-Feb;67(1-2):1-12. Epub 2006 Mar 31.

PMID:
16698419
19.

Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?

Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW.

Med Hypotheses. 2008 Nov;71(5):802-4. doi: 10.1016/j.mehy.2008.06.022. Epub 2008 Aug 8.

PMID:
18691831
20.

Stability of regulatory T-cell lineage.

Hori S.

Adv Immunol. 2011;112:1-24. doi: 10.1016/B978-0-12-387827-4.00001-2. Review.

PMID:
22118405

Supplemental Content

Support Center